Olema Pharmaceuticals

In October 2020, Olema Pharmaceuticals announced a Series C Preferred stock financing of $85 million. The Company is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast and gynecologic cancers.

Liquid Wire

In July 2020, Liquid Wire announced a Series A round financing of $10 million. The Company is focused on developing and manufacturing flexible wiring and components to enable electronic circuitry in wearables to be used in multiple healthcare applications, as well as industrial (including safety). These applications typically involve dynamic environmental forces, such as changing temperature, movement, and humidity while maintaining reliable and consistent conductivity.

Annexon Biosciences

In July 2020, Annexon Biosciences announced a Series C round financing of $100 million. Annexon Biosciences is a clinical-stage biopharmaceutical company developing a pipeline of therapies for patients with complement-mediated autoimmune and neurodegenerative disorders. 

Somatus

In June 2020, Somatus announced a Series C round financing of $64 million. Focused on value-based kidney care, Somatus partners with leading health plans, health systems, and nephrology and primary care groups to provide integrated care for patients with or at risk of developing kidney disease.

Civetta Therapeutics, LLC

In December 2019, Civetta Therapeutics, LLC announced a $53 million Series A round financing. Civetta is a Cambridge, Massachusetts-based therapeutics company, founded to advance new medicines through small molecule targeting of beta-propeller domains with the goal of developing important drugs for cancers and other diseases.

Nkarta Therapeutics

In August 2019, Nkarta announced a crossover Series B round financing of $114 million. Nkarta is developing genetically modified natural killer cells (NK) cell therapies for cancer.The Company’s lead program is an NKG2D CAR for the treatment of hematological malignancies and solid tumors.

Stelexis Therapeutics, LLC

In January 2019, Stelexis Therapeutics, LLC, a New York-based cancer therapeutics company, announced that it closed a $43 million Series A financing to expand its proprietary platform to discover and selectively target pre‐cancerous stem cells.

Strata Oncology

In the 2nd quarter of 2018, Deerfield participated in a $26 million Series B financing round for Strata Oncology. The company provides an end-to-end clinical trial platform for precision oncology that expands patient access to precision oncology clinical trials and accelerates clinical trial enrollment.

The company expects to deploy this capital to expand access to precision trials in new hospital systems, fund the FDA approval process for in vitro diagnostics and further develop its technology and analytical capabilities.

Dracen Pharmaceuticals, Inc.

In March 2018, Deerfield invested $36 million in Dracen Pharmaceuticals, Inc as part of a $40 million Series A. Dracen is a private company developing proprietary anti-cancer drugs discovered at the Johns Hopkins University and the Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences.

Quartet Health

In December 2017 Deerfield participated in a $40 million Series C financing round for Quartet Health, a tech-enabled healthcare company that brings together physicians, mental health providers and payors to improve patient outcomes and lower healthcare costs. Quartet will use the new capital to expand its core engineering and product capabilities across its primary care, behavioral health and patient platforms, scale its machine learning team, and continue to build out its provider network, partner success and new business development functions.